The study is to investigate the non-inferior efficacy of Paroxetine Controlled Release to Paroxetine Immediate Release, as well as the drug tolerability profile when treated on patients with Major Depression.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
362
GSK Investigational Site
Guangzhou, Guangdong, China
GSK Investigational Site
Baoding, Hebei, China
GSK Investigational Site
Changsha, Hunan, China
GSK Investigational Site
Scores on depression rating scale at treatment week 1,2,3,4,6 and 8.
Scores on clinical impression severity and improvement items at treatment week 1, 2,3,4,6,8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Nanjing, Jiangsu, China
GSK Investigational Site
Xi'an, Shaanxi, China
GSK Investigational Site
Xi'an, Shaanxi, China
GSK Investigational Site
Chengdu, Sichuan, China
GSK Investigational Site
Kunming, Yunnan, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
...and 1 more locations